ACADIA PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
ACAD$18.28+10.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEM ENTS OF CASH FLOWS
| Years Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cash flows from operating activities | |||
| Net income (loss) | $391,000 | $226,451 | $(61,286) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||
| Stock-based compensation | 52,135 | 67,049 | 66,421 |
| Amortization of premiums and accretion of discounts on investment securities | (5,424) | (9,304) | (7,533) |
| Amortization of intangible assets | 10,889 | 14,963 | 4,093 |
| Gain on sale of non-financial asset | — | (146,515) | — |
| Gain on strategic investment | — | — | (5,109) |
| Depreciation | 871 | 920 | 1,459 |
| Loss on sale of investment securities | — | — | 524 |
| Deferred income taxes (including benefit from valuation allowance) | (249,879) | — | — |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | (22,718) | (472) | (36,072) |
| Interest and other receivables | (20,818) | (1,873) | (3,198) |
| Inventory | (18,197) | (49,550) | (28,808) |
| Prepaid expenses and other current assets | (3,845) | (16,590) | (17,693) |
| Operating lease right-of-use assets | 8,667 | 7,502 | 5,769 |
| Other assets | (2,856) | 117 | (33) |
| Accounts payable | (5,289) | (1,351) | 4,797 |
| Accrued liabilities | (19,265) | 71,061 | 93,170 |
| Operating lease liabilities | (6,516) | (7,598) | (5,872) |
| Long-term liabilities | 1,081 | 2,909 | 6,073 |
| Net cash provided by operating activities | 109,836 | 157,719 | 16,702 |
| Cash flows from investing activities | |||
| Purchases of investment securities | (692,565) | (505,095) | (369,985) |
| Sale and maturity of investment securities | 493,529 | 328,565 | 429,780 |
| Proceeds from sale of non-financial asset | — | 146,515 | — |
| Proceeds from sale of strategic investment | — | — | 12,253 |
| Net purchases of property and equipment | (4,690) | (523) | (50) |
| Payment of milestone and contingent payments in connection with asset acquisition | (98,838) | — | (40,000) |
| Net cash (used in) provided by investing activities | (302,564) | (30,538) | 31,998 |
| Cash flows from financing activities | |||
| Proceeds from issuance of common stock, net of issuance costs | 49,883 | 6,845 | 25,129 |
| Net cash provided by financing activities | 49,883 | 6,845 | 25,129 |
| Effect of exchange rate changes on cash | 26 | (94) | (18) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (142,819) | 133,932 | 73,811 |
| Cash, cash equivalents and restricted cash | |||
| Beginning of year | 328,359 | 194,427 | 120,616 |
| End of year | $185,540 | $328,359 | $194,427 |
| Supplemental disclosure of cash flow information: | |||
| Cash paid for income taxes | $25,170 | $19,521 | $5,850 |
| Supplemental disclosure of noncash information: | |||
| Accrued inventory purchases | $1,219 | $1,268 | $— |
| Stock based compensation capitalized | $426 | $425 | $79 |
| Accrued milestone and contingent payments in connection with asset acquisition | $— | $98,838 | $29,583 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.